Next-Generation Modalities, Precision Trials, and AI-Driven Breakthroughs in Oncology

Roundtable summary

Next-Generation Modalities, Precision Trials, and AI-Driven Breakthroughs in Oncology

The next wave of oncology innovation is here: multi-targeted, multi-modality therapies. ADCs, bispecifics and cell therapies are leading the way – and experts predict this is just the beginning. But transforming these promising pathways into practice requires strategic navigation and collaboration.

Hear from industry leaders on the trends, critical considerations and future advances shaping oncology R&D, including:

Emerging oncology trends, including growing pipeline diversity and smarter, mechanism-driven development

Advances in multi-targeted, multi-modality therapies, including progress in drugging previously undruggable targets

How lean biotechs can balance investment and risk through efficient, biomarker-led precision trial design

The rising importance of early alignment with regulators and payers to support value-based care and commercialization